Answers are grounded in this paper and cite their sources.
Neutropenia is a recognized but undercharacterized toxicity of dabrafenib/trametinib (D+T) combination therapy in melanoma. We conducted a retrospective single-center analysis of 171 patients treated with D+T between 2015-2020. Any-grade neutropenia occurred in 44 patients, predominantly within the first three months. Neutropenia was more frequent in women and in patients treated in the adjuvant setting. Most cases were mild and resolved spontaneously; dose reduction was required in 32% of affected patients. Infectious complications occurred in 13.6% of neutropenic patients, with three severe cases. Concomitant eosinopenia was observed in 50%, suggesting impairment of a shared myeloid progenitor via MAPK pathway inhibition.
No takes yet. Share an insight, caveat, or question.
Fareau et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: